Literature DB >> 8104177

Analysis of responses to serotonin in the pulmonary vascular bed of the cat.

T J McMahon1, J S Hood, B D Nossaman, P J Kadowitz.   

Abstract

Pulmonary vascular responses to serotonin (5-hydroxytryptamine; 5-HT) were investigated in the intact-chest cat under constant-flow conditions. Injections of 5-HT into the perfused lobar artery in doses of 1-30 micrograms caused dose-related increases in lobar arterial pressure and, at doses of 3-30 micrograms, decreases in systemic arterial pressure. Left atrial pressure was not changed, and responses to 5-HT were not altered by a thromboxane receptor blocking agent. Responses to 5-HT were blocked by ketanserin in doses that did not alter responses to agonists that increase pulmonary vascular resistance by various mechanisms. The ketanserin-induced blockade was not surmountable and at a dose of 0.5 mg/kg iv persisted for > 4 h. Prazosin and yohimbine, selective alpha 1- and alpha 2-adrenoceptor antagonists, were without effect on the pressor response to 5-HT, and ketanserin did not reduce responses to norepinephrine or the alpha 1-agonists, phenylephrine and methoxamine. 5-HT and the thromboxane mimic, U-46619, produced large increases in pulmonary vascular resistance; however, U-46619 was 300 times more potent than 5-HT. 5-HT increased lobar arterial pressure when the lung was perfused with dextran, and increases in lobar arterial pressure in response to 5-HT were not diminished when lobar ventilation was interrupted but were enhanced by N omega-nitro-L-arginine methyl ester and to a small extent by meclofenamate. The present data suggest that increases in pulmonary vascular resistance in the cat in response to 5-HT are due to activation of an S2 receptor in undefined "resistance vessel elements." These data suggest that pulmonary vasoconstrictor responses to 5-HT may be modulated to a small extent by release of a vasodilator prostaglandin and endothelium-derived nitric oxide but are not dependent on activation of thromboxane receptors, changes in bronchomotor tone, and interaction with alpha 1-receptors or with formed elements in blood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104177     DOI: 10.1152/jappl.1993.75.1.93

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  6 in total

1.  Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.

Authors:  Ali Sadoughi; Kari E Roberts; Ioana R Preston; Ginny P Lai; Deborah H McCollister; Harrison W Farber; Nicholas S Hill
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

2.  SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn.

Authors:  Anick Bérard; Odile Sheehy; Jin-Ping Zhao; Évelyne Vinet; Sasha Bernatsky; Michal Abrahamowicz
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

Review 3.  Serotonin reuptake inhibitor-induced perinatal complications.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Sudden Onset of Severe Pulmonary Hypertension in a Preterm Infant: A Case Report on the Role of Maternal Use of Serotonin Re-Uptake Inhibitors During Pregnancy and Concurrent Risk Factors.

Authors:  Isabella Buffoni; Silvia Buratti; Marisa F Mallamaci; Stefano Pezzato; Elisabetta Lampugnani; Francesca Buffelli; Ezio Fulcheri; Andrea Moscatelli
Journal:  Front Pediatr       Date:  2022-06-10       Impact factor: 3.569

5.  Dilatation induced by 5-HT in the middle meningeal artery of the anaesthetised cat.

Authors:  Geoffrey Andrew Lambert; Cathy Donaldson; Karen Lisa Hoskin; Peter Michael Boers; Alessandro Stefano Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-05-07       Impact factor: 3.000

Review 6.  Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications.

Authors:  Jillan Cantor Sackett; Ronald A Weller; Elizabeth B Weller
Journal:  Curr Psychiatry Rep       Date:  2009-06       Impact factor: 5.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.